Blog
Published October 19, 2021
Executive Summary
The American Society of Cell & Gene Therapy (ASCGT) wrapped up their 2021 conference earlier this year, which covered a range of topics, from new scientific advances to the evolving pricing and market access dynamics surrounding cell and gene therapies (CGT). Trinity had the opportunity to attend the conference, which brought together stakeholders from across the CGT landscape to discuss some of the challenges and opportunities within the space today.
In this post we will cover the most…
Read Now
Webinars
Available On Demand
October 28, 2021 | 1:00-1:45 pm ET
Trinity MedTech, a part of Trinity Life Sciences, invites you to our webinar, MedTech in the Post-COVID World: Where Do We Go From Here? We will share data from our real-world evidence team on key sectors within the broader MedTech industry to show the impact of COVID on different MedTech lines of business. We will also explore what the implications are moving forward for companies/brands. In particular, what are best practice companies/brands doing…
Watch Now
White Papers
The Example of ASCO 2021
While people were expecting to return to in-person conferences soon, the emergence of the Delta variant and the possibility of future unknown variants, combined with uneven vaccination rates, has created significant uncertainty about how soon that can happen. Trinity Life Sciences wanted to understand what perceptions medical conference attendees had of the new virtual conference world, what advantages and disadvantages they saw in it, and how manufacturers performed at engaging their audiences. We performed a…
Read Now
Blog
Published October 6, 2021
Executive Summary
Given the majority of cell and gene therapies to date have offered the potential of a cure, pricing and access considerations are likely to differ for non-curative agents that are entering this space
Although non-curative cell and gene therapies have demonstrated clinical efficacy (e.g., for multiple myeloma and wet age-related macular degeneration), manufacturers will need to communicate additional value offerings of these therapies to payers in order to avoid pushback and enhance access potential, such as:
Robust evidence…
Read Now
Webinars
Available On Demand
December 1st, 2021 | 1:00 pm EST
In today’s highly competitive market, innovation and creativity are critical to create a strong Brand Strategy that supports meaningful differentiation. A key challenge for life sciences companies in 2022 will be to identify the clearest strategies to address brand performance and assessing brand health for their unique context. Whether your brand is on-market already or is preparing for launch, leveraging a nuanced, evidence-based view of performance drivers – from prescriber adoption, to payer…
Watch Now
Blog
Published September 30, 2021
Written by Caspar Kengeter and Manon Ricard…
Read Now
Blog
Published September 27, 2021
Paige Prostate is the first artificial intelligence (AI)-based software designed to identify areas of concern (i.e., high likelihood of containing cancer) on a prostate biopsy image so they can be flagged for further review by a pathologist. The program is intended to be used as an adjunct tool to the review of digital scanner slide images from prostate biopsies.
The program was reviewed through the De Novo pathway, a regulatory pathway for low-to-moderate risk novel devices. The FDA authorization is based…
Read Now
Blog
Published September 22, 2021
Executive Summary
In June 2021, Walmart announced it is partnering with Novo Nordisk to produce its own private label insulin, ReliOn, at a discount to Novo Nordisk’s currently available fast-acting insulin
Through this partnership, Americans with a high-deductible health plan (HDHP) or without insurance can save up to 75% and purchase the insulin at their local Walmart
Novo Nordisk’s key competitors, Eli Lilly and Sanofi are likely to respond with a similar partnership or price-cut for their insulin to remain…
Read Now
Webinars
Available On Demand
According to a TGaS Advisors’ large landscape study, 45% of all machine learning commercial use cases in the life sciences industry were for finding patients, often for HCP alerts and targeting. In fact, if you are not doing patient finding alerts/targeting, you are probably behind the industry.Come join TGaS Advisors, a division of Trinity Life Sciences, as we share the “ins and outs” of patient finding, including learnings from our study. It’s clear that patient finding can have a big…
Watch Now
Blog
Published September 8, 2021
Executive Summary
The healthcare sector is becoming increasingly attractive, and despite the risk of an expensive failed venture, non-traditional players have and will likely continue to take their chances to enter the field
While the market has been profitable for some players such as Fujifilm and Nestlé, others have had a challenging time competing in this uniquely complex market (e.g., Kodak and Heaven)
Trinity’s take: Non-traditional players that have been successful in tapping into the healthcare sector seem to follow a…
Read Now
